To know the safety and efficacy of Antioxidants in Patients of chronic obstructive pulmonary disease.

Comparative Evaluation of Efficacy and safety Profile of Antioxidants-N-Acetyl-L-Cysteine(NAC) and Superoxide Dismutase(SOD)Supplementation in Patients of COPD.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/01/005432

Enrollment

150

Registered

2015-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic obstructive pulmonary disease (COPD)

Interventions

Intervention1: SOD Group: Patients on standard therapy + oral Superoxide Dismutase(SOD) 1 tab OD (140 I.U)for 12 weeks Intervention2: NAC Group: Patients on standard therapy + oral N-acetyl-L-cystei

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of COPD, diagnosed clinically and spirometrically. 2.Having complaints of breathlessness, tightness in chest, cough with or without sputum. 3.Cases of Grade I to III COPD as per GOLD guidelines.

Exclusion criteria

Exclusion criteria: 1.Complicated cases of chronic obstructive pulmonary disease with respiratory failure . 2.Patient with bronchial asthma. 3.Pregnant and lactating mothers. 4.Patients with clinically relevant, abnormal laboratory values suggesting an unknown disease requiring further investigation. 5.Psychotic patients 6.HIV/HBsAg/AntiHCV positive and immune compromised patients.

Design outcomes

Primary

Measure	Time frame
PFT Timepoint: 0 4 8 12th week	—

Secondary

Measure	Time frame
Haemogram with ESR Blood sugar E.C.G X-ray chest P/A view L.F.T. R.F.T.Timepoint: 0 4 8 12th week	—

Countries

India

Contacts

Public ContactDr Asif hussain

JNMCH, AMU

waseemnakhat@gmail.com09897686003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026